Search
Adlai Nortye Ltd
ANLAdd to Watchlist
9.490USD
-1.110-10.47%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
296.44MMarket Cap
LossP/E TTM
More Details of Adlai Nortye Ltd Company
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
Adlai Nortye Ltd Info
Ticker SymbolANL
Company nameAdlai Nortye Ltd
IPO dateSep 29, 2023
CEOBirgerson (Lars Erik)
Number of employees123
Security typeDepository Receipt
Fiscal year-endSep 29
Addressc/o PO Box 309
CityGRAND CAYMAN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCayman Islands
Postal codeKY1-1104
Phone18482307430
Websitehttps://www.adlainortye.com/
Ticker SymbolANL
IPO dateSep 29, 2023
CEOBirgerson (Lars Erik)
Company Executives of Adlai Nortye Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Mr. Shaorong Liu
Mr. Shaorong Liu
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Ming Lun (Alan) Tse
Mr. Ming Lun (Alan) Tse
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Kaiyang Tang
Dr. Kaiyang Tang
Senior Vice President, Global Head of Clinical Operations
Senior Vice President, Global Head of Clinical Operations
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Mr. Shaorong Liu
Mr. Shaorong Liu
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Ming Lun (Alan) Tse
Mr. Ming Lun (Alan) Tse
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
FAQs
Who are the top five shareholders of Adlai Nortye Ltd?
The top five shareholders of Adlai Nortye Ltd are: Mr. Yang Lu
How many institutions hold shares of Adlai Nortye Ltd (ANL)?
As of 2026Q1, 13 institutions hold shares of Adlai Nortye Ltd, with a combined market value of approximately 3.40M, accounting for 7.18% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3307188.00.